FutureGen
AbbVie and FutureGen announce license agreement for IBD therapy
June 14, 2024Research and Development FutureGen, Gastrointestinal tract, ibd, inflammatory bowel disease
AbbVie and FutureGen Biopharmaceutical have announced a license agreement for the development of FG-M701, a next-generation TL1A antibody for the …
Latest content
Highlighting the value of lab research for healthcare innovation
November 2, 2026
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
